# TCR1188-ABC Cells in KRAS-mutated Cancers

> **NCT07594067** · PHASE1 · NOT_YET_RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 30 (estimated)

## Conditions studied

- Cholangiocarcinoma
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Pancreatic Adenocarcinoma

## Interventions

- **BIOLOGICAL:** TCR1188-ABC cells
- **DRUG:** Fludarabine + Cyclophosphamide combination
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT07594067
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2042-07
- **Final completion:** 2042-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07594067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07594067, "TCR1188-ABC Cells in KRAS-mutated Cancers". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07594067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*